Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian I Carr

Showing results (91-100 of 187) with videos related to

Pageof 19
Sort By:
Journal of Hepatology|November 3, 2004
Involvement of c-Myc in growth inhibition of Hep 3B human hepatoma cells by a vitamin K analogLisheng Ge, Ziqiu Wang, Meifang Wang, et al.
Seminars in Oncology|April 7, 2015
A comparison of patients with hepatitis B- or hepatitis C-based advanced-stage hepatocellular carcinomaBrian I Carr, Vito Guerra, Jennifer L Steel, et al.
Liver Research|October 19, 2023
Discordance among aggressiveness characteristics of hepatocellular carcinoma: Portal vein thrombosis and multifocality, related to tumor size, but not to serum alpha-fetoprotein levelBrian I Carr, Vito Guerra, Volkan Ince, et al.
Hepatology International|August 12, 2009
Gender-based outcomes differences in unresectable hepatocellular carcinomaShama C Buch, Venkateswarlu Kondragunta, Robert A Branch, et al.
Cancer|January 13, 2010
Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort studyBrian I Carr, Venkateswarlu Kondragunta, Shama C Buch, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|November 23, 2006
Health-related quality of life: Hepatocellular carcinoma, chronic liver disease, and the general populationJennifer L Steel, Kapil Chopra, Marion C Olek, et al.
International Journal of Cancer|February 26, 2011
Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivoGang Wei, Meifang Wang, Terry Hyslop, et al.
World Journal of Gastroenterology|April 25, 2018
Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolizationYossi Ventura, Brian I Carr, Issac Kori, et al.
Human Pathology|September 19, 2008
Hepatobiliary effects of 90yttrium microsphere therapy for unresectable hepatocellular carcinomaMichael A Nalesnik, Michael Federle, David Buck, et al.
Molecular Cancer Therapeutics|July 5, 2006
PM-20, a novel inhibitor of Cdc25A, induces extracellular signal-regulated kinase 1/2 phosphorylation and inhibits hepatocellular carcinoma growth in vitro and in vivoSiddhartha Kar, Meifang Wang, Wei Yao, et al.
Pageof 19

Showing results (91-100 of 187) with videos related to

Sort By:
Pageof 19
Journal of Hepatology|November 3, 2004
Involvement of c-Myc in growth inhibition of Hep 3B human hepatoma cells by a vitamin K analogLisheng Ge, Ziqiu Wang, Meifang Wang, et al.
Seminars in Oncology|April 7, 2015
A comparison of patients with hepatitis B- or hepatitis C-based advanced-stage hepatocellular carcinomaBrian I Carr, Vito Guerra, Jennifer L Steel, et al.
Liver Research|October 19, 2023
Discordance among aggressiveness characteristics of hepatocellular carcinoma: Portal vein thrombosis and multifocality, related to tumor size, but not to serum alpha-fetoprotein levelBrian I Carr, Vito Guerra, Volkan Ince, et al.
Hepatology International|August 12, 2009
Gender-based outcomes differences in unresectable hepatocellular carcinomaShama C Buch, Venkateswarlu Kondragunta, Robert A Branch, et al.
Cancer|January 13, 2010
Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort studyBrian I Carr, Venkateswarlu Kondragunta, Shama C Buch, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|November 23, 2006
Health-related quality of life: Hepatocellular carcinoma, chronic liver disease, and the general populationJennifer L Steel, Kapil Chopra, Marion C Olek, et al.
International Journal of Cancer|February 26, 2011
Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivoGang Wei, Meifang Wang, Terry Hyslop, et al.
World Journal of Gastroenterology|April 25, 2018
Analysis of aggressiveness factors in hepatocellular carcinoma patients undergoing transarterial chemoembolizationYossi Ventura, Brian I Carr, Issac Kori, et al.
Human Pathology|September 19, 2008
Hepatobiliary effects of 90yttrium microsphere therapy for unresectable hepatocellular carcinomaMichael A Nalesnik, Michael Federle, David Buck, et al.
Molecular Cancer Therapeutics|July 5, 2006
PM-20, a novel inhibitor of Cdc25A, induces extracellular signal-regulated kinase 1/2 phosphorylation and inhibits hepatocellular carcinoma growth in vitro and in vivoSiddhartha Kar, Meifang Wang, Wei Yao, et al.
Pageof 19